Examples of 'icatibant' in a sentence
Meaning of "icatibant"
icatibant (noun): A pharmaceutical drug used to treat hereditary angioedema, a rare genetic disorder characterized by episodes of severe swelling
Show more definitions
- A peptidomimetic drug used for the symptomatic treatment of acute attacks of hereditary angioedema.
How to use "icatibant" in a sentence
Basic
Advanced
icatibant
Icatibant has a reversible effect on the gonadotrophins.
Firazyr contains the active substance icatibant.
It is unknown whether icatibant is excreted in human breast milk.
Results do not indicate a carcinogenic potential for icatibant.
The treatment effect of icatibant was confirmed by secondary efficacy endpoints.
Withdraw the required volume of icatibant solution.
The influence of race on icatibant pharmacokinetics has not been evaluated.
The active substance is icatibant.
Icatibant had no effect on the fertility of male mice and rats.
The medications ecallantide and icatibant may be used to treat attacks.
Elderly patients have been shown to have increased systemic exposure to icatibant.
Icatibant is a potent.
In a standard battery of in vitro and in vivo tests icatibant was not genotoxic.
Limited data suggest that icatibant exposure is not influenced by hepatic or renal impairment.
Adrenal gland hypertrophy was seen to reverse after cessation of icatibant treatment.
See also
Metabolism Icatibant is extensively metabolized by proteolytic enzymes to inactive metabolites.
Older people have been shown to have increased systemic exposure to icatibant.
Adverse reactions reported with icatibant in the phase III clinical trials.
Firazyr is a solution for injection that contains the active substance icatibant.
The authors concluded that icatibant was effective in treating acute attacks of HAE.
Elderly people have been shown to have increased systemic exposure to icatibant.
Transferring the icatibant solution to the graduated syringe,.
Patients with symptoms of laryngeal angioedema received open label treatment with icatibant.
Patients were randomized to receive either icatibant 30 mg or placebo by subcutaneous injection.
A two-year study was conducted in rats to assess the carcinogenic potential of icatibant.
Icatibant was shown to be a competitive antagonist when the bradykinin challenge dose was increased 4-fold.
Data suggests that gender and weight do not have a significant influence on icatibant pharmacokinetics.
In both rats and dogs, repeated use of icatibant resulted in effects on reproductive organs.
Formal drug-drug interaction studies have not been conducted with icatibant acetate.
The pre-filled icatibant syringe and all other components are for single use only.
Long-term studies to determine the carcinogenic potential of icatibant have not been conducted to date.
Icatibant is a selective competitive antagonist of BK2R and ecallantide inhibits the action of kallikrein.
Genotoxiciy In a standard battery of in vitro and in vivo tests, icatibant was not genotoxic.
Icatibant had no effect on the fertility of male mice and rats see section 5.3.
Little is known about the effects of icatibant on the bradykinin B1 receptor.
Each ml of the solution contains 10mg of icatibant.
Each pre-filled syringe delivers 3 mL containing icatibant acetate equivalent to 30 mg icatibant.
Following subcutaneous administration, the absolute bioavailability of icatibant is 97.
Icatibant is a relatively new medication that is used to treat acute ( short-lasting ) episodes of swelling.
Each pre-filled syringe contains 30 milligrams of icatibant as acetate.
Another medication, icatibant ( Firazyr ), directly blocks bradykinin activity to prevent excess inflammation in hereditary angioedema.
Table 1, Adverse reactions reported with icatibant.
Icatibant Purcellin oil ( marketed by Dragocco ).
Firazyr 30 mg solution for injection in pre-filled syringe Icatibant.
Icatibant was administered once, subcutaneously, at a dose of 30 mg.
Each pre-filled syringe of 3 ml contains icatibant acetate equivalent to 30 mg icatibant.
Icatibant and N-nitro-L-arginine methyl ester abolished the effects of kallikrein, indicating a kinin-B2 receptor-nitric oxide-mediated event.
Each pre-filled syringe of Firazyr contains 30 mg icatibant in 3 ml.
The active substance is icatibant 30 milligrams ( as acetate ) in 3 ml solution for injection in each.
FIRAZYR is available in a single dose pre-filled syringe containing 30 mg/3mL icatibant as acetate.
